39th week of 2021 patent applcation highlights part 9 |
Patent application number | Title | Published |
20210299016 | SULFATE-FREE PERSONAL CARE COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING POLLUTION DAMAGE TO SKIN - Personal care compositions and methods for treating or preventing lipid peroxidation of skin with the same are disclosed. The personal care composition may include a carrier and a surfactant system present in an effective amount to treat or prevent lipid peroxidation of skin. The surfactant system may include at least one amphoteric surfactant and at least one anionic surfactant. The method may include contacting the personal care composition with the skin and exposing the skin to pollution. Methods for formulation a personal care composition for treating or preventing lipid peroxidation of skin are also disclosed. The method may include determining an oxidation protection factor (OPF) of one or more components, using the OPF to select at least one component of the one or more components, and combining the at least one component of the one or more components with a carrier to form the personal care composition. | 2021-09-30 |
20210299017 | ANTIMICROBIAL COMPOSITION - An antimicrobial composition is described herein. The composition comprises an antimicrobial agent, a sequestering agent, a release agent, and an optional dispersing agent. Hand sanitizers and sprays comprising the composition are also described, along with related methods of sanitizing items, such as hands, surfaces, and personal protective equipment. | 2021-09-30 |
20210299018 | Oral Care Compositions and Methods of Use - This invention relates to oral care compositions comprising guanidine, zinc citrate and zinc oxide, and a fluoride source, as well as to methods of using and of making these compositions. | 2021-09-30 |
20210299019 | METHODS FOR TREATING HYPERPIGMENTATION AND COMPOSITIONS FOR SAME - Compositions and methods for treating hyperpigmentation using an aminothiol and a biguanide are described herein. | 2021-09-30 |
20210299020 | Personal Care Compositions - Described herein are personal care compositions comprising a sulfate-free surfactant system and a preservative system comprising an organic acid; along with methods of making and using same. | 2021-09-30 |
20210299021 | A COMPOSITION FOR LIGHTENING AND REDUCING HYPER PIGMENTATION OF SKIN - The invention relates to a novel composition of a cosmetic product for topical application. More particularly, the invention relates to a cosmetic composition for lightening of skin and reducing hyper pigmentation. In the main embodiment the present invention provides a novel composition of a cosmetic product for lightening of skin and reducing skin pigmentation comprising of three key ingredients: niacinamide, 4-substituted resorcinol, and hinokitiol (β-thujaplicin) and/or extract of the parts of trees in the family Cupressaceae. The present invention provides a novel cosmetic composition which is easy to formulate; and is mild on skin. The composition can also be used as an agent for preventing skin tanning in topical products. | 2021-09-30 |
20210299022 | COMPOSITION FOR THE TREATMENT OF NAIL FUNGUS - Compositions for the topical treatment of fungal infections in nails, comprising at least one physiologically acceptable carboxylic acid capable of reducing the pH in keratinous tissue, in particular nails, of a treated person below 4.0, preferably in the range of 1.5-4.0, a physiologically acceptable carrier comprising at least one C1-C4 alkyl ester of lactic acid, and at least one physiologically acceptable fluorescent whitening agent. The invention relates to the use of said composition for the preparation of a product suitable for treatment of fungal infections. The invention also relates to the use of said composition for the treatment of a fungal infection. | 2021-09-30 |
20210299023 | COMPOSITIONS AND METHODS FOR HAIR GROWTH - The present invention is directed to compositions and methods comprising the use of bimatoprost and cyclosporine, used concurrently and in combination, to grow hair and for the treatment of all types of hair loss conditions such as but not limited to alopecia areata. The present invention is also directed to compositions containing bimatoprost and cyclosporine A to grow hair on the scalp and other areas of the body and methods of administration of the compositions. | 2021-09-30 |
20210299024 | Keratin Compositions - The invention relates to compositions comprising a keratin pigment material. The keratin pigment material comprises dyed keratin particles. Compositions comprising keratin pigment material such as inks, paints and cosmetic formulations have advantageous properties compared to similar compositions in which conventional pigment materials are used as colourants. | 2021-09-30 |
20210299025 | HAIR CLEANSING COMPOSITION - Hair care cleansing composition comprising—a) from 1 to 50 wt % of a cleansing surfactant selected from the group consisting of anionic surfactant, zwitterionic or amphoteric surfactant, non-ionic and mixtures thereof; and b) from 0.01 to 3 wt %, by weight of the total composition, of defibrillated primary cell wall material comprising cellulose microfibrils, wherein • the defibrillated primary cell wall material comprises up to 20 wt. % of water, based on the total weight of the fibrils; and wherein • the cellulose has an average degree of crystallinity of less than 50%, and wherein • the defibrillated primary cell wall material comprises polyols distributed between the fibrils. | 2021-09-30 |
20210299026 | HAIR STYLING COMPOSITION AND SPRAY SYSTEM - The present disclosure relates to a hair styling composition. According to one example of the present disclosure, there is provided a hair styling composition having a little beading phenomenon or flaking phenomenon as well as excellent style holding force of the set hair, and capable of providing excellent detergency even after use. | 2021-09-30 |
20210299027 | LEAVE-ON LIGHT OIL HAIR COMPOSITION - The present disclosure relates to leave-on light oil hair compositions that comprise a blend of non-cyclic silicone and non-silicone ingredients. The leave-on light oil hair compositions, which do not contain D4, D5 or D6 silicones, are particularly useful in methods for imparting durable resistance to breaking, frizz control, shine and/or volume definition with a soft feel to hair. | 2021-09-30 |
20210299028 | LEAVE-ON PENETRATING OIL HAIR COMPOSITION - The present disclosure relates to leave-on penetrating oil hair compositions that comprise a blend of non-cyclic silicone and non-silicone ingredients. The leave-on penetrating oil hair compositions, which do not contain D4, D5 or D6 silicones, are particularly useful in methods for imparting durable resistance to breaking, frizz control, shine and/or volume definition with a soft feel to hair. | 2021-09-30 |
20210299029 | LEAVE-ON SERUM HAIR COMPOSITION - The present disclosure relates to leave-on serum hair compositions that comprise a blend of non-cyclic silicone and non-silicone ingredients. The leave-on serum hair compositions, which do not contain D4, D5 or D6 silicones, are particularly useful in methods for imparting durable resistance to breaking, frizz control, shine and/or volume definition with a soft feel to hair. | 2021-09-30 |
20210299030 | OIL-BASED COSMETIC PREPARATION - The present invention provides an oil-based cosmetic which is excellent in terms of a matte texture, while being highly stable. An oil-based cosmetic which is characterized by containing the following components (a)-(e).
| 2021-09-30 |
20210299031 | Sprayable Film Forming Compositions For Improving The Performance Of Topical Preparations - A spray-on film forming composition is designed to work with another topical preparation, such as a conventional cosmetic foundation or skincare product. The film forming composition is in direct contact with the cosmetic or skincare product. The spray-on film forming composition may be applied underneath a topical preparation (as a primer), on top of a topical preparation (as a mask), or both, depending on the benefit conferred. The spray-on film forming compositions of the invention are able to improve wearability and removability, increase shine, and deliver active ingredients. They are very clear, flexible and comfortable. | 2021-09-30 |
20210299032 | IMPROVING THE QUALITY OF FORMULATION CLARITY & SENSORY WITH AN EXTRACT COMPRISING A XANTHONE ANTIOXIDANT - A cosmetic composition and a method of preparing a cosmetic composition that includes at least one xanthonoid; at least about 10 wt. % of Vitamin C; at least one hydrotrope from about 0.8 to about 1.5 wt. %.; a solvent comprising water, at least one glycol and ethyl alcohol; pantothenic acid; hydroxypropyl methylcellulose; and wherein the cosmetic composition is stable, translucent and lubricated. | 2021-09-30 |
20210299033 | COMPOSITIONS COMPRISING CARUM CARVI AND ROSMARINUS OFFICINALIS EXTRACTS AND METHODS OF USING SAME - Provided are compositions comprising | 2021-09-30 |
20210299034 | A Topical Composition - The present invention relates to a topical composition. Particularly, the present invention relates to a topical composition that comprises degallated tea extract that comprises less than 0.2% gallic acid on dry weight basis and provides improved skin lightening. | 2021-09-30 |
20210299035 | Personal Care Compositions Comprising Cannabidiol and Licorice - Disclosed are personal care compositions comprising cannabidiol dissolved in a carrier oil, e.g., hemp seed oil, and licorice extract, wherein the weight ratio of the cannabidiol to the licorice extract is in the range of from 1:6 to 1:40, as well as methods of using these compositions. | 2021-09-30 |
20210299036 | CONDITIONED MEDIUM AND EXTRACELLULAR MATRIX COMPOSITIONS AND USES THEREOF - The present invention is directed to a methods for the stimulation of hair, lash and/or nail growth by the administration of extracellular matrix (ECM) and/or conditioned culture media (CCM) compositions in combination with active agents such as minoxidil and bimatoprost. The combination of hypoxic CCM and an active agent acts to promote hair, lash and/or nail growth and/or promote hair follicle development and/or activate or stimulate on an area of the skin when administered to the region of skin or tissue in need of growth or repair in a subject. | 2021-09-30 |
20210299037 | ADHERENT ORAL PHARMABIOTIC DELIVERY STRIP - An oral pharmabiotic system is disclosed for improving oral, dental, and systemic health by repopulating and reshaping the flora within a patient's oral environment in a manner that overcomes the deficiencies of prior oral probiotic products. By formulating the pharmabiotic system as a strip for adhesive placement within a patients' oral cavity, preferably against the buccal mucosa, alveolar mucosa, oral labial mucosa, or a dental appliance, and configuring the parameters of the strip such that neither disadhesion nor complete dissolution occurs for at least a period of at least three hours during daytime use and at least six hours during nighttime use, the probiotic payload contained within may remain in the oral cavity for a sufficient length of time required for the probiotics to activate, replicate, and displace existing harmful oral pathobiotics. | 2021-09-30 |
20210299038 | METHOD TO PREVENT AND TREAT OCULAR CATARACT BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS - A method is provided to prevent and to treat ocular cataract by using Calcium channel blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors, or angiotensin receptor blockers (ARB), and more particularly, to a method to prevent and treat ocular cataract by using calcium channel blockers, Angiotensin-Converting Enzyme Inhibitors, or angiotensin receptor blockers that are not taken orally, but administered by ophthalmic preparation directly onto or into the eye where ocular cataract is formed, to increase the capillary network and augment the blood supply to the ocular lens. | 2021-09-30 |
20210299039 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASE BY CONTACT LENS MEDIATED DRUG DELIVERY - The disclosure provides an ocular drug delivery system that includes a contact lens and a drug delivery portion, which may include a compound having the formula X—(CH2)n-Z, wherein X is a photocrosslinkable group. Advantageously, the drug delivery portion may aid in loading a high concentration of a negatively-charged therapeutic agent into the ocular drug delivery system. Additionally, the disclosed ocular drug delivery system may aid in controlled delivery of the negatively-charged therapeutic agent to the eye of a patient over a period of about 4 to about 24 hours. | 2021-09-30 |
20210299040 | CHEWING GUM COMPRISING NICOTINE - The invention relates to a chewing gum comprising at least a gum core comprising nicotine polacrilex, at least a one outer coating covering the core, comprising at least one sugar alcohol or mixtures of sugar alcohols and, at least a one portion fused onto the outer coating, wherein the portion comprises nicotine bitartrate or nicotine ditartrate dihydrate and at least one sugar alcohol or a mixture of sugar alcohols and at least one buffer present in the coating and/or in a portion fused to the coating. | 2021-09-30 |
20210299041 | Aerosol-generating device for the inhalation administration of an antisense-molecule-containing composition - The invention relates to the use of an aerosol-generating device for generating an aerosol of a composition, for administering the composition by inhalation, wherein the composition comprises at least one antisense-molecule. The aerosol-generating device has a membrane having a perforation, wherein the composition for generating the aerosol is brought into contact with the membrane, and the membrane of the aerosol-generating device are caused to vibrate. The perforation is formed of at least one group of passage openings, wherein each passage opening of a group has a diameter of at least 3 μm and at most 5 μm at the narrowest point of the passage opening, and wherein the at least one group of passage openings comprises at maximum 500 passage openings per mm 2 of the membrane. | 2021-09-30 |
20210299042 | CANNABINOID-CONTAINING PRODUCTS, CONTAINERS, SYSTEMS, AND METHODS - One example of a cannabinoid-containing product includes a cannabinoid-containing liquid for ingestion and an additive for production of a cannabinoid-containing aerosol for inhalation. A container for such a product could include a container body holding the cannabinoid-containing liquid and additive, and a cover to seal the container body. Another type of container includes a container body holding contents that include a liquid for ingestion, a cover to seal the container body, and an aerosolizer packaged with the container to aerosolize a cannabinoid from the contents for airborne delivery of a cannabinoid-containing aerosol for inhalation. Other embodiments, including multi-container packages, uses, and methods of use, are also disclosed. | 2021-09-30 |
20210299043 | SOLUTION AND METHOD FOR REDUCING THE VIRULENCE OF VIRUSES, BACTERIA,YEASTS, OR FUNGUS - A method of reducing the virulence of microbes in or on the human body and a method of sanitizing or disinfecting a surface, area, object, or porous or non porous material is provided. The methods comprise applying or injecting a solution having an effective amount of a conjugated diene for substantially reducing the virulence of the microbes or sanitizing or disinfecting a surface, area, object, or porous or non porous material. | 2021-09-30 |
20210299044 | SYSTEMS AND METHODS FOR DELIVERY OF DRUGS AND OTHER SUBSTANCES COMPRISING DEEP EUTECTIC SOLVENTS - The present invention generally relates to compositions, including liquid compositions, for the delivery of pharmaceutical agents and other beneficial substances, e.g., in various forms, including but not limited to a liquid, patch, cream, lotion, or gel. For example, some aspects of the present invention are generally directed to formulations comprising deep eutectic solvents. In some cases, such formulations may exhibit surprisingly low melting points, for example, such that the formulations are liquid at ambient temperatures. Such formulations, in some cases, may be useful for facilitating absorption of pharmaceutical agents or beneficial substances that are poorly soluble in water. Also, in certain embodiments, such formulations may be substantially free of water, which some pharmaceutical agents, such as aspirin, can be sensitive to. In addition, in some cases, the formulations can be present in various delivery vehicles, such as patches, creams, lotions, gels, and the like. Such formulations, in some cases, may be useful for containing pharmaceutical agents or beneficial substances that are poorly soluble in water, or are sensitive to water, etc. Accordingly, such formulations may be liquid without necessarily being aqueous, and accordingly can be administered to a subject orally, in liquid form. Other aspects are generally directed to methods of making such compositions, methods of using such compositions, kits including such compositions, etc. | 2021-09-30 |
20210299045 | TRAMADOL HYDROCHLORIDE SOLUTION - Disclosed herein is an analgesic solution for the treatment of pain comprising a pain-relieving effective amount of tramadol or a pharmaceutically acceptable salt thereof, a method of treating pain by administering said analgesic solution to a subject in need thereof, a kit that includes containers of the analgesic solution, and a dosing regimen for the analgesic solution. | 2021-09-30 |
20210299046 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC CONDITIONS - The invention provides emulsion compositions comprising at least one cannabinoid compound, and methods for making the same. The emulsion compositions are stable, well tolerated and are capable of delivering therapeutically effective amounts of cannabiniods to target sites, including sites on the surface of and/or within an eye. Also provided are methods of using the compositions to provide ocular neuroprotection and/or to treat ophthalmic conditions such as glaucoma. | 2021-09-30 |
20210299047 | ZINC MELOXICAM COMPLEX MICROPARTICLE MULTIVESICULAR LIPOSOME FORMULATIONS AND PROCESSES FOR MAKING THE SAME - Embodiments of the present disclosure are related to multivesicular liposome formulations encapsulating zinc meloxicam complex microparticles. Methods of making the zinc meloxicam complex microparticles and administering the zinc meloxicam complex microparticles encapsulated in multivesicular liposome formulations and their use as medicaments are also provided. | 2021-09-30 |
20210299048 | SOLID FORMS OF CANNABIDIOL AND USES THEREOF - Disclosed herein are cocrystals of cannabidiol and a coformer containing 5-6 membered rings comprised of carbon and nitrogen atoms, wherein the 5-6 membered rings can be unsaturated or saturated and the rings contain 1 to 2 nitrogen atoms. Cocrystals of cannabidiol and a coformer selected from L-proline, D-proline, tetramethylpyrazine, and 4,4′-dipyridyl are also disclosed herein | 2021-09-30 |
20210299049 | Method of preparing degradable and environment responsive composite microgels - A method of preparing degradable and environment responsive composite microgels, belonging to polymer material synthesis and biomaterial technology fields. Firstly, a copolymer of L-malic acid and 6-hydroxyhexanoate is prepared; then, N,N,N′,N′-tetramethyl cystamine is prepared. The copolymer and N,N,N′,N′-tetramethyl cystamine are mixed in an organic solvent to form a mixed solution which is added into excess distilled water to produce composite microgels. The microgels have advantages of mild preparing conditions, fast reaction speed without catalysts, no impurity remained, and controllable degradation rate. The microgels can load anticancer drug doxorubicin hydrochloride, showing environment responsive controlled release due to introduction of carboxyl groups and disulfide bonds. | 2021-09-30 |
20210299050 | Solid Oral Sulfate Salt Formulations For Cleansing A Colon And Methods Of Using Same - Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed. | 2021-09-30 |
20210299051 | PHARMACEUTICAL COMPOSITION FOR AMELIORATION OF ADVERSE SIDE EFFECTS - The present invention provides a pharmaceutical composition ( | 2021-09-30 |
20210299052 | Oral Tablet For Delivery Of Active Ingredients To The Gastrointestinal Tract - An oral tablet for delivery of active ingredients to the gastrointestinal tract includes a population of particles and an active ingredient to be delivered to the gastrointestinal tract. The population of particles includes directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting in induced saliva generation upon mastication of the tablet, wherein the tablet is designed to be masticated and designed to deliver the active ingredient to the gastrointestinal tract as part of the saliva generated upon mastication of the tablet. | 2021-09-30 |
20210299053 | CONTROLLED RELEASE FORMULATION COMPRISING FLAVOXATE - The present invention relates to a controlled release oral formulation comprising about 400 mg to about 800 mg of flavoxate salt as an active ingredient, suitable polymers, binders, and excipients, and lacking an acidifying agent. The present invention also provides a method of preparing the controlled release oral formulation of about 400 mg to 800 mg of flavoxate salt. The controlled release formulation of present invention may comprise micronized particles of drug. The controlled release formulation has a controlled release profile of up to 24 hours, that is pH independent, and that is alcohol dose dumping risk-free. | 2021-09-30 |
20210299054 | PHARMACEUTICAL METHODS AND COMPOSITIONS - The disclosure provides a method of producing a pharmaceutical composition. The method comprises (a) dissolving an active pharmaceutical ingredient (API) in a liquid vehicle to form a liquid medicament; (b) contacting the liquid medicament with a pharmaceutical carrier; (c) contacting the composition comprising the liquid medicament and pharmaceutical carrier with a pharmaceutical coating material to form a liqui-mass composition; and (d) pelletising the liqui-mass composition to form the pharmaceutical composition. | 2021-09-30 |
20210299055 | Treatment of Solid Cancerous Tumors by Oral Administration of a Halogenated Xanthene - The present invention contemplates a method of treating a solid cancerous tumor in a mammalian subject by the oral administration of a solid cancerous tumor-effective amount of a halogenated xanthene (HX), the lactone thereof, a pharmaceutically acceptable salt, or a C | 2021-09-30 |
20210299056 | Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods - Various embodiments are directed to color-coded and size-calibrated polymeric particles comprising an acrylate-based hydrogel core incorporating one or more chromophores of interest, and an outer shell comprising polyphosphazenes of formula I, useful for various therapeutic and/or diagnostic procedures. In various embodiments, the color-coded and size-calibrated polymeric particles can be employed in any particle-mediated procedure, including as embolic agents, dermal fillers, and various implantable devices for a broad range of clinical and cosmetic applications. The incorporation of a particular chromophore formulation that correlates with a pre-determined size specificity for implantable and loadable polymeric particles (“color-coded and size-calibrated”) enables the visual detection and identification of particles exhibiting a particular size of interest, and minimizes the probability of user-introduced or procedural errors. | 2021-09-30 |
20210299057 | PROCESS FOR PREPARING MICROPARTICLES CONTAINING GLATIRAMER ACETATE - The present invention provides an improved process for preparing microparticles containing glatiramer acetate having low levels of residual organic solvent(s), in particular dichloromethane. The microparticles are incorporated into long acting parenteral pharmaceutical compositions in depot form that are suitable for subcutaneous or intramuscular implantation or injection, and that may be used to treat multiple sclerosis. | 2021-09-30 |
20210299058 | Intracellular Delivery System for mRNA Nucleic Acid Drugs, Preparation Method and Application Thereof - A delivery system for mRNA nucleic acid drugs, a preparation method and an application thereof are provided. The delivery system includes lipid nanoparticles for loading one or more kinds of mRNA molecules, wherein the lipid nanoparticles are prepared from raw materials including an ionizable cationic lipid, a phospholipid auxiliary lipid, cholesterol, and a polyethylene glycol-derivatized phospholipid. In the mRNA nucleic acid drug targeted intracellular delivery system based on the non-viral carrier of the present invention, the mRNA is concentrated and loaded by the electrostatic interaction between the ionizable cationic lipid and the mRNA. Phospholipid auxiliary lipid component-mediated pH sensitivity and late endosomal escape enable mRNA nucleic acid drugs to be efficiently delivered to target cells and then released into the cytoplasm of the target cells for exerting a pharmacodynamic effect. | 2021-09-30 |
20210299059 | INJECTABLE PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR - An injectable pharmaceutical composition and a preparation method therefor. Specifically, the pharmaceutical composition comprises apixaban nanoparticles, a surface stabilizer, and may further comprise a sedimentation inhibitor. The pharmaceutical composition has good stability and is suitable for industrial mass production. | 2021-09-30 |
20210299060 | CO-DELIVERY OF NUCLEIC ACIDS FOR SIMULTANEOUS SUPPRESSION AND EXPRESSION OF TARGET GENES - Nanoparticulate pharmaceutical formulations and methods for co-delivery of two or more species of nucleic acids for simultaneous suppression and expression of target genes in a cell, are provided. The nanoparticles encapsulate two or more nucleic acid species. The first nucleic acid suppresses expression of a gene or product thereof, e.g., inhibitory nucleic acid, such as antisense, siRNA, miRNA, Dicer siRNA, piRNA, etc. The second nucleic acid increases expression of, or encodes, an endogenous or exogenous protein or polypeptide, e.g., an mRNA. The first and second nucleic acid species simultaneously target or affect the same or different cellular processes within a cell including communication, senescence, DNA repair, gene expression, metabolism, necrosis, and apoptosis. | 2021-09-30 |
20210299061 | DENDRITIC NANOGEL CARRIERS AND METHOD OF PRODUCTION - The present invention relates to a nanogel of nanoparticles. The nanoparticles comprise self-assembled dendritic containing polymers having at least one dendritic hydrophobic segment forming the core and at least one hydrophilic segment forming the shell. | 2021-09-30 |
20210299062 | CANNABINOID COMPOSITIONS AND METHODS OF TREATMENT - The present disclosure is drawn to oral cannabinoid compositions and methods for modulating inflammation in a subject. In some aspects, oral administration of an amount of a cannabinoid in a carrier to a subject reduces cytokine levels in the subject to a greater degree than an equivalent amount of the cannabinoid administered in an edible oil. | 2021-09-30 |
20210299063 | AFFINITY MEDICANT CONJUGATE - In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The medicant moiety can be a toxin including an acylfulvene or a drug moiety. The affinity moiety can be an antibody, a binding protein, a steroid, a lipid, a growth factor, a protein, a peptide or non peptidic. The affinity moiety can be covalently bound to the medicant via a linker. Novel linkers that can be directed to cysteine, arginine or lysine residues based on solution pH allow greater flexibility in preserving and/or generating specific epitopes in the AMC. | 2021-09-30 |
20210299064 | METHOD OF TREATING PATIENTS WITH LENNOX-GASTAUT SYNDROME - A method of treating symptoms of Lennox-Gastaut syndrome in a patient diagnosed with Lennox-Gastaut syndrome, by administering an effective dose of fenfluramine to that patient over a period of time sufficient to reduce or completely eliminate seizures in the patient. The fenfluramine may be administering in an oral liquid formulation on a daily basis of 0.7 mg/kg/day, over a period of weeks until seizures are reduced by 25% or more, 50% or more, 75% or more. | 2021-09-30 |
20210299065 | METHODS OF TREATMENT FOR ANOREXIA NERVOSA, BULIMIA AND RELATED CLINICAL SYNDROMES - The present disclosure relates generally to methods of treatment for eating disorders, such as anorexia nervosa and bulimia nervosa, and related clinical syndromes by maintaining a subject in need of treatment on a ketogenic diet and administering a ketamine to the subject. | 2021-09-30 |
20210299066 | NOVEL AMINOTHIOL REDUCTION OF ISCHEMIA-REPERFUSION-INDUCED CELL DEATH - Members of the PrC-210 family of aminothiols, including PrC-211 and PrC-252, are shown to be highly effective in reducing ischemia-reperfusion injury in two preclinical models, including kidney transplant and myocardial infarct. Compositions and methods employing members of the PrC-210 family of aminothiols are disclosed for suppressing ischemia-reperfusion-induced cell and organ toxicities in a number of settings, significantly including organ transplant and myocardial infarct. | 2021-09-30 |
20210299067 | GUANIDINIUM DERIVATIVES AS IMMUNITY-INDUCING AGENT - Use of an immune modulator composition and/or pharmaceutical composition comprising Guanidinium Derivatives substances for use in the manufacture of a medicament for the treatment of an autoimmune disease or autoimmune disorder, including certain vascular disorders. Immunity-inducing agent composition having a pH of between 5.5 and 7.5 containing at least 100 mg/l, preferably at least 300 mg/l of a combination food protecting agent and guanidinium derivatives, particularly to combinations of oligo(2-(2-ethoxy)ethoxy ethyl guanidinium chloride), poly(hexamethylendiamine guanidiniumchloride), polyetheramines, triethyleneglycol diamine, mushrooms, enzymes, PGPR, amino acids, antioxidants like humic acids and some natural products like phytotherapeutic plant extracts. | 2021-09-30 |
20210299068 | ANTIMICROBIAL COMPOSITIONS COMPRISING CHLORHEXIDINE - Chlorhexidine gluconate is a commonly used disinfectant that is soluble in aqueous solutions. Because it is a common disinfectant, chlorhexidine gluconate is often used in alcohol solvents, but chlorhexidine gluconate is not soluble in C | 2021-09-30 |
20210299069 | PSAMMAPLIN A FOR MODULATING IDO EXPRESSION - The present invention relates to ex vivo methods using psammaplin A, the compound of formula (I) | 2021-09-30 |
20210299070 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY - Disclosed are methods of treating creatine transporter deficiency, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that increases transport of a substrate by a mutant or wild-type creatine transporter. Also disclosed are methods of increasing transport of guanidinoacetic acid or a salt thereof across the blood-brain barrier of a mammal, and methods of decreasing accumulation or the concentration of guanidinoacetic acid or a salt thereof in a mammalian cell. | 2021-09-30 |
20210299071 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY - A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition comprising the compound. The compound is useful for the treatment a disease resulting from pathologic inflammation, such as inflammatory bowel disease, psoriasis or rheumatoid arthritis. | 2021-09-30 |
20210299072 | METHODS AND COMPOSITIONS FOR TREATMENT OF PAIN USING CAPSAICIN - The invention provides methods and compositions for treatment of pain, such as joint pain, using capsaicin in a procedure that attenuates transient burning sensation experienced by patients due to capsaicin administration. The methods desirably provide relief from joint pain, such as osteoarthritic knee joint pain, for an extended duration, such as at least about 3 months, 6 months, 9 months, or 1 year. To attenuate the adverse side effect of a transient burning sensation caused by capsaicin-induced neuronal excitation, the methods utilize a cooling article, such as a material wrap cooled via a circulating fluid, to reduce the temperature of tissue to be exposed to capsaicin to within a certain range for certain durations of time, optionally in combination with administering a local anesthetic agent, resulting in the substantial reduction or even elimination of transient burning sensation caused by capsaicin. | 2021-09-30 |
20210299073 | COMPOSITIONS AND METHODS FOR REGULATING BODY WEIGHT AND METABOLIC SYNDROMES - A composition comprising an active agent that inhibits acyl-coenzyme A:cholesterol acyltransferase (ACAT) is provided. With the composition, food intake can be suppressed, and/or body weight can be reduced, and/or metabolic disorders can be prevented and/or treated. | 2021-09-30 |
20210299074 | COMPOSITIONS AND METHODS FOR REGULATING BODY WEIGHT AND METABOLIC SYNDROMES - A composition comprising an active agent that inhibits acyl-coenzyme A:cholesterol acyltransferase (ACAT) is provided. With the composition, food intake can be suppressed, and/or body weight can be reduced, and/or metabolic disorders can be prevented and/or treated. | 2021-09-30 |
20210299075 | Use of a virucidal preparation in the nasal cavity for prevention of transmission or contraction of viral illnesses, or to shorten the duration of, or lessen the severity of viral illnesses. - A method of reducing or inhibiting the contraction or communication of viral upper respiratory illnesses is proposed. Application of a virucidal preparation containing one or more organic acids (e.g. malic acid) with one or more surfactants (e.g. sodium C | 2021-09-30 |
20210299076 | AMINO ACID FORMULATIONS AND USES THEREOF - An amino acid formulation is described herein comprising free amino acids consisting essentially of: free amino acids of lysine, glycine, threonine, valine, tyrosine, aspartic acid, isoleucine, and serine; and optionally, tryptophan; and one or more electrolytes selected from Na | 2021-09-30 |
20210299077 | LIPOSOMAL REDUCED GLUTATHIONE (LRG) IN COMBINATION WITH IVERMECTIN FOR THE TREATMENT OF COVID-19 - For prophylaxis and treatment of Covid-19, the invention claimed proposes a combination and associated methods of a combination of ivermectin and liposomal reduced glutathione from Your Energy Systems, LLC of Palo Alto, Calif. An alternative dosing schedule is proposed for elderly or in adult individuals with compromise of the immune system. Pedriatic doses are also specified. | 2021-09-30 |
20210299078 | Inducing Proliferation of Cardiomyocytes and Therapeutic Uses Related Thereto - This disclosure relates to methods of treating or preventing heart malformations or cardiovascular diseases comprising administering an effective amount of thyroid hormone in combination with i) an agent that decreases DUSPS and/or DUSP6 expression and/or ii) a beta-adrenergic blocking agent to a subject in need thereof. In certain embodiments, this disclosure relates to in vivo and in vitro methods of inducing proliferation of cardiomyocytes using agents or combinations of agents disclosed herein. | 2021-09-30 |
20210299079 | MONOMETHYL FUMARATE-CARRIER CONJUGATES AND METHODS OF THEIR USE - Disclosed are conjugates of monomethyl fumarate and a carrier group or aminocarrier group, or a pharmaceutically acceptable salt thereof. In the conjugates, monomethyl fumarate acyl is covalently bonded to the carrier group or aminocarrier group through a carbon-oxygen bond that is cleavable in vivo. The carrier group may include a core, e.g., a monosaccharide, a sugar acid (e.g., acid monosaccharide), a sugar alcohol, or a catechin polyphenol. The aminocarrier group may include a core, e.g., an aminomonosaccharide. The carrier group or aminocarrier group may include, e.g., at least one short chain fatty acid acyl, at least one tryptophan analogue, at least one ketone body, or at least one pre-ketone body. Also disclosed are pharmaceutical compositions containing the conjugates and methods of their use. | 2021-09-30 |
20210299080 | METHOD OF TREATMENT - Embodiments of the invention relate generally to increasing adult height in individuals with no light perception (NLP). | 2021-09-30 |
20210299081 | SOLID CANNABINOID FORMULATION FOR ORAL ADMINISTRATION - The invention provides solid, self-emulsifying compositions for oral administration. The compositions can comprise a population of particles comprising a cannabinoid or a terpene, a surfactant, and a solid carrier. The invention also encompasses methods for the preparation and use thereof. | 2021-09-30 |
20210299082 | FISETIN COMPOSITION AND A METHOD OF MAKING THE SAME - A fisetin composition is disclosed herein. The fisetin composition comprises fisetin and one or more elements so that the solubility of the fisetin is increased, especially in view of higher effectiveness, potency, and/or bioavailability in treatments. Apparatus for use with the fisetin composition are disclosed herein. | 2021-09-30 |
20210299083 | Novel Uses of Halogenated Xanthenes in Oncology and Virology - A method for treating a viral infection of a mammalian subject that comprises administering a virus-inhibiting amount of a halogenated xanthene, a pharmaceutically acceptable salt, an alkyl ester or amide or aromatic ester or amide derivative thereof as disclosed within, to that mammalian subject. A method of inducing a type I interferon response in a mammalian subject that presents with a microbial infection, cancerous tumor or hematological malignancy that comprises administering an amount of a halogenated xanthene as discussed above, effective to induce the type I interferon response. A method of enhancing a mammalian immunogen-specific immune response that comprises contacting mammalian cells, in vivo or present in a mammalian cell growth supporting medium, with an adjuvant-effective amount of a halogenated xanthene as discussed above, and an immunogen to which that response is to be enhanced. | 2021-09-30 |
20210299084 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SENSORINEURAL HEARING LOSS, CONTAINING FORSKOLIN AND RETINOIC ACID AS ACTIVE INGREDIENTS - A pharmaceutical composition containing forskolin and retinoic acid as active ingredients which is suitable for preventing or treating sensorineural hearing loss is disclosed. A pharmaceutical composition containing forskolin and retinoic acid as active ingredients has an excellent effect of preventing, alleviating or treating hearing loss caused by ototoxic drugs during anticancer treatment, and thus is useful as a pharmaceutical composite preparation capable of reducing side effects of anticancer drugs and, additionally, as an agent for preventing or treating sensorineural hearing loss. | 2021-09-30 |
20210299085 | METHODS FOR THE TREATMENT OF INFLAMMATION ASSOCIATED WITH INFECTION - The present invention provides methods of treating inflammation associated with infection, and methods of preventing or reducing the severity of sepsis caused by inflammation associated with infection, in an individual comprising, consisting essentially of or consisting of the steps of administering a therapeutically effective amount of idronoxil, or derivative, pharmaceutically acceptable salt, ester, amide, polymorph and/or prodrug thereof to the individual, wherein the individual is diagnosed with, or suspected of having, early stage organ damage caused by inflammation associated with infection. | 2021-09-30 |
20210299086 | COMPOSITIONS COMPRISING COMBINATIONS OF PURIFIED CANNABINOIDS, WITH AT LEAST ONE FLAVONOID, TERPENE, OR MINERAL - Disclosed herein are new compositions having combinations of purified cannabinoids. One embodiment of this disclosure provides compositions having one or more purified cannabinoids in combination with a purified terpene. One embodiment of this disclosure provides compositions having one or more purified cannabinoids in combination with a purified flavonoid. One embodiment of this disclosure provides compositions having one or more purified cannabinoids in combination with a purified mineral. | 2021-09-30 |
20210299087 | ORAL COMPOSITIONS DELIVERING THERAPEUTICALLY EFFECTIVE AMOUNTS OF CANNABINOIDS - Oral compositions provide delivery of cannabinoids to a subject. The oral compare chewable, fast- or slow-dissolving once placed in the mouth of a subject. | 2021-09-30 |
20210299088 | METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONS - A method and composition for treating viral infections using a combination of naturally occurring compounds is provided. The method includes administering to a patient at risk of or diagnosed with a viral infection a composition including therapeutically effective amounts of a myricetin and hesperitin to treat viral infections include coronavirus. | 2021-09-30 |
20210299089 | ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS - The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions. | 2021-09-30 |
20210299090 | Methods for Treating Parkinson?s Disease by Administering Resiniferatoxin - There is disclosed a method for treating Parkinson's Disease (PD) comprising administering an effective amount of Resiniferatoxin (RTX) by an intrathecal or intracisternal administration. In some embodiments, the dose of RTX for an adult human is from about 0.1 μg to about 100 μg. | 2021-09-30 |
20210299091 | METHOD OF PREVENTING COVID-19 INFECTION - A method of preventing COVID-19 infection in a healthy individual, the method comprising the steps of a) providing the healthy individual; b) administering, on day 1, 10,000 mg of vitamin C, 40,000 mg of vitamin D, and 50 mg of zinc; c) administering daily, on days 2 and 3, 10,000 mg of vitamin c and 50 mg of zinc; d) administering daily, on days 4 through 7, 3,000 mg of vitamin c and 50 mg of zinc; and e) repeating steps b) and c) for 1 to 23 weeks. | 2021-09-30 |
20210299092 | ENALAPRIL FORMULATIONS - Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction. | 2021-09-30 |
20210299093 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR PULMONARY HYPERTENSION COMPRISING UNSATURATED 5-MEMBERED HETEROCYCLE-CONTAINING COMPOUND - The present invention provides a preventive or therapeutic agent for pulmonary hypertension, including a compound represented by the following formula (I) or a salt thereof: where: -A- represents —NH—, —S—, or —O—; R | 2021-09-30 |
20210299094 | METHODS OF UPREGULATING TIPARP AS ANTICANCER STRATEGIES - The present disclosure is directed to a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a TiPARP agonist, wherein the TiPARP agonist may be, for example, a tamoxifen compound (e.g., tamoxifen or derivative thereof), flavone or derivative thereof, isoflavone or derivative thereof, diindolylmethane compound, or chlorinated dibenzo-p-dioxin (CDBD) compound or derivative thereof. The cancer may be associated with elevated expression of HIF-1α and may be selected from, for example, breast cancer, colon cancer, lung cancer, skin cancer, brain cancer, blood cancer, cervical cancer, liver cancer, prostate carcinoma, pancreas carcinoma, gastric carcinoma, ovarian carcinoma, renal cell carcinoma, mesothelioma, and melanoma. The cancer may, in some embodiments, exclude breast cancer. | 2021-09-30 |
20210299095 | METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE - A method of modulating ribonucleotide reductase activity in a neoplastic cell includes administering to the cell an amount of a hydrazone or hydrazine ribonucleotide reductase modulator (RRmod), the amount being effective to inhibit neoplastic cell growth. | 2021-09-30 |
20210299096 | MICROORGANISM MIXTURES, MOLECULES DERIVED THEREFROM, AND METHODS OF USE THEREOF - The present invention is directed to a composition comprising a Tryptophol derivative and a 4-Ethyl-Phenol derivative, and at least one acceptable carrier. Further provided are methods for reducing the formation of load of organic-based contaminant. | 2021-09-30 |
20210299097 | COMPOSITIONS FOR A DIETARY SUPPLEMENT TO IMPROVE SLEEP - A composition for improving sleep. In one embodiment, the composition comprises L-Tryptophan, L-Theanine, Reishi mushroom extract, Uridine, a polyphenol, and paeoniflorin. In certain embodiments, the composition further comprises citrus bioflavonoid extract, γ-Oryzanol, holy basil extract, saffron extract, | 2021-09-30 |
20210299098 | SELECTIVE ESTROGEN RECEPTOR MODULATOR FOR TREATMENT OF PANCREATIC CANCER - Disclosed is a method for treating of cancer, specifically pancreatic cancer by administering a selective estrogen receptor modulator (SERM), e.g., levormeloxifene, alone or in combination with one or more additional cancer therapies. | 2021-09-30 |
20210299099 | THERAPEUTIC AGENT FOR NON-MOTOR SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE - The purpose of the present invention is to provide: a therapeutic agent or a recurrence preventive agent for serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease; and a method for treating the aforesaid symptoms or preventing the recurrence of the same. A compound represented by formula (1) [wherein each symbol is as defined in the description] or a pharmaceutically acceptable salt thereof can exhibit an effect of treating serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease and/or an effect of preventing the recurrence of the same. | 2021-09-30 |
20210299100 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS - The present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof; | 2021-09-30 |
20210299101 | SYSTEMS, METHODS, AND KITS FOR DIAGNOSTICS AND TREATMENT OF VIRAL RESPIRATORY INFECTION - The present disclosure includes methods, systems, kits and compositions for treating, preventing and diagnosing viral infections, specifically SARS-CoV-2 infections, with an anti-androgen and anti-thyroid medication, a thyroid receptor antagonist, a TGF-β inhibitor or a combination thereof. The present disclosure also describes methods and compositions for the treatment of viral respiratory diseases, specifically SARS-CoV-2 infections, including anti-androgens, anti-thyroid medications, thyroid receptor antagonists, TGF-β inhibitors, RXR inhibitors, furin inhibitors or other agents to disrupt the androgen signaling. | 2021-09-30 |
20210299102 | METHODS AND COMPOSITIONS FOR TREATMENT OF MYELODYSPLASTIC SYNDROMES AND/OR ACUTE MYELOID LEUKEMIAS - Disclosed are methods for treating a myelodyspastic syndrome (MDS) and/or an acute myeloid leukemia (AML) in an individual in need thereof. Further disclosed are compositions for use in the disclosed methods, used for treating a myelodyspastic syndrome (MDS) and/or an acute myeloid leukemia (AML) in an individual in need thereof. | 2021-09-30 |
20210299103 | COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SULFONAMIDE DERIVATIVE AS ACTIVE INGREDIENT - The present disclosure relates to a composition for treating cancer and inhibiting cancer metastasis, which contains a sulfonamide derivative as an active ingredient. More specifically, the composition containing a sulfonamide derivative as an active ingredient may be provided as a cancer therapeutic agent or a cancer metastasis inhibitor since the sulfonamide derivative from which antibiotic susceptibility has been completely removed exhibits superior effect of inhibiting cancer cell multiplication and migration by effectively inhibiting the secretion of exosomes by cancer cells and exhibits no cytotoxicity to normal cells. | 2021-09-30 |
20210299104 | EXTENDED RELEASE INJECTABLE FORMULATIONS COMPRISING AN ISOXAZOLINE ACTIVE AGENT, METHODS AND USES THEREOF - This invention relates to extended release injectable formulations for combating parasites in animals, comprising at least one isoxazoline active agent, a pharmaceutically acceptable polymer, and a solvent. This invention also provides for improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the extended release injectable formulations of the invention to the animal in need thereof. | 2021-09-30 |
20210299105 | SELECTIVE INHIBITION OF T FOLLICULAR HELPER CELLS FOR TREATMENT OF AUTOIMMUNE DISORDERS - Disclosed herein is a method of inhibiting T Follicular Helper (TFH) cell-mediated differentiation and/or activation in a subject. This method involves administering to a subject in need of treatment for an autoimmune disorder a eukaryotic translation initiation factor 4E (eIF4E) inhibitor to inhibit TFH cell-mediated differentiation and/or activation in the subject. Also disclosed is a method of inhibiting T Follicular Helper (THF) cell differentiation or TFH cell activity. | 2021-09-30 |
20210299106 | AZOPHENOLS AS ERG ONCOGENE INHIBITORS - Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II) | 2021-09-30 |
20210299107 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS - The present disclosure provides, inter alia, a compound having the structure: | 2021-09-30 |
20210299108 | SERINE PROTEASE INHIBITOR FOR TREATING CORONAVIRUS INFECTION - The disclosure is directed to WX-671, as (L)- or (D)-enantiomers, and as E- or (Z)-isomers or (E/Z)-mixtures, and as free bases or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection. | 2021-09-30 |
20210299109 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS - The present application discloses a method for identifying an agent for the treatment or prevention of cancer or metastatic cancer comprising the steps of contacting stem cell with a potential agent, and identifying an agent that induces differentiation, or inhibits stem cell pluripotency or growth of the stem cell, wherein such agent is determined to be an anti-cancer agent. | 2021-09-30 |
20210299110 | AZAINDOLES AS INHIBITORS OF HPK1 - Azaindole compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the azaindole compounds. | 2021-09-30 |
20210299111 | EIF4A INHIBITOR COMBINATIONS - The present disclosure relates to methods for ameliorating or treating an eIF4A dependent condition or disease in a subject in need thereof. The methods of the disclosure comprise administering to the subject a therapeutically effective amount of at least one eukaryotic translation initiation factor 4A (eIF4A) inhibitor and a therapeutically effective amount of at least one cyclin-dependent kinase (CDK) inhibitor. | 2021-09-30 |
20210299112 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE - The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: | 2021-09-30 |
20210299113 | TRPV4 ANTAGONISTS - The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists. | 2021-09-30 |
20210299114 | METHODS FOR PREVENTING AND TREATING RETINAL DAMAGE - Methods of treating, reducing the risk of, preventing, or alleviating at least one symptom of a retinal disease, injury, or condition in a subject involve administering a pharmaceutically effective amount of kynurenic acid to the subject. The kynurenic acid may be administered intravenously or intravitreally. Systems for treating retinal diseases, injuries, or conditions are also disclosed and may include an administration device. | 2021-09-30 |
20210299115 | HETEROARYL INHIBITORS OF PAD4 - The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders. | 2021-09-30 |